Author: Wallace, Megan; Woodworth, Kate R.; Gargano, Julia W.; Scobie, Heather M.; Blain, Amy E.; Moulia, Danielle; Chamberland, Mary; Reisman, Nicole; Hadler, Stephen C.; MacNeil, Jessica R.; Campos-Outcalt, Doug; Morgan, Rebecca L.; Daley, Matthew F.; Romero, José R.; Talbot, H. Keipp; Lee, Grace M.; Bell, Beth P.; Oliver, Sara E.
Title: The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021 Cord-id: kyg0ft4r Document date: 2021_5_21
ID: kyg0ft4r
Snippet: The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pf
Document: The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) in persons aged ≥16 years (1); on December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the vaccine in the same age group (2). As of May 12, 2021, approximately 141.6 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥16 years.* On May 10, 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years (1). On May 12, 2021, ACIP issued an interim recommendation†for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,§ using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥12 years under an EUA is interim and will be updated as additional information becomes available.
Search related documents:
Co phrase search for related documents- acip evidence and additional information available: 1, 2
- acip immunization practices advisory committee and additional consideration: 1
- acip immunization practices advisory committee and additional information: 1, 2, 3, 4, 5
- acip immunization practices advisory committee and additional information available: 1, 2, 3, 4
- acip immunization practices advisory committee and adolescent child: 1, 2
- acip immunization practices and additional consideration: 1
- acip immunization practices and additional information: 1, 2, 3, 4, 5
- acip immunization practices and additional information available: 1, 2, 3, 4
- acip immunization practices and adolescent child: 1, 2
- acip present and additional consideration: 1
- acip recommendation and additional information: 1, 2, 3, 4
- acip recommendation and additional information available: 1, 2, 3
- acip recommendation and adolescent child: 1, 2
- acute sars infection and additional information: 1, 2, 3, 4, 5, 6
- acute sars infection and adolescent child: 1, 2
Co phrase search for related documents, hyperlinks ordered by date